Refine
Has Fulltext
- yes (14)
Is part of the Bibliography
- yes (14)
Document Type
- Journal article (14)
Language
- English (14)
Keywords
- Cancer (3)
- Nude-mice (3)
- cancer (3)
- Agent (2)
- GLV-1H68 (2)
- Therapy (2)
- breast cancer (2)
- breast-tumors (2)
- cancer treatment (2)
- carcinoma (2)
- metastasis (2)
- oncolytic virotherapy (2)
- therapy (2)
- vaccinia virus (2)
- BV-2 (1)
- Biochemie (1)
- Breast-tumors (1)
- COX-2 (1)
- Carcinoma (1)
- Deletion (1)
- Expression (1)
- GBM (1)
- GI-101A tumor xenografts (1)
- Human Sodium/Iodide symporter (1)
- IMA2.1 (1)
- In-Vivo (1)
- In-vivo (1)
- Inhibitor (1)
- NA+/I-symporter (1)
- NA/I symporter (1)
- OSC (1)
- Protein (1)
- Recombinant vaccinia (1)
- Regression (1)
- Reporter gene (1)
- Tissue (1)
- Transporter (1)
- VACV (1)
- acute myeloid leukemia (1)
- adenovirus (1)
- angiogenesis (1)
- animal-model (1)
- antibodies (1)
- ascites (1)
- blood (1)
- bone morphogenetic protein (BMP) (1)
- cancer stem cells (CSCs) and differentiation (1)
- carcinomas (1)
- cell cultures (1)
- cell-line (1)
- colorectal (1)
- conservation (1)
- conserving surgery (1)
- dogs (1)
- engineered measles-virus (1)
- enzyme-linked immunoassays (1)
- epithelial-mesenchymal transition (1)
- gene expression (1)
- glioblastoma multiforme (GBM) (1)
- glv-1h68 (1)
- identification (1)
- in-vitro (1)
- in-vitro propagation (1)
- lines (1)
- lymph nodes (1)
- malignant pleural mesothelioma (1)
- mastectomy (1)
- matrix metalloproteinases (1)
- metastases (1)
- metastatic tumors (1)
- mice (1)
- microenvironment (1)
- microglia (1)
- modulation of virus replication (1)
- mouse models (1)
- neutrophils (1)
- nude mice (1)
- nude-mice (1)
- oncolytic viruses (1)
- pancreatic cancer (1)
- polarization (1)
- positron-emission-tomography (1)
- prostate (1)
- prostate cancer (1)
- radiation-therapy (1)
- replicating adenovirus (1)
- reporter gene (1)
- sodium-iodide symporter (1)
- stage-i (1)
- subpopulation (1)
- thyroid-cancer (1)
- tumor microenvironment (1)
- tumors (1)
- vaccinia virus (VACV) (1)
- viral replication (1)
- viral therapy (1)
- virotherapy (1)
Metastatic tumor cells in body fluids are important targets for treatment, and critical surrogate markers for evaluating cancer prognosis and therapeutic response. Here we report, for the first time, that live metastatic tumor cells in blood samples from mice bearing human tumor xenografts and in blood and cerebrospinal fluid samples from patients with cancer were successfully detected using a tumor cell-specific recombinant vaccinia virus (VACV). In contrast to the FDA-approved CellSearch system, VACV detects circulating tumor cells (CTCs) in a cancer biomarker-independent manner, thus, free of any bias related to the use of antibodies, and can be potentially a universal system for detection of live CTCs of any tumor type, not limited to CTCs of epithelial origin. Furthermore, we demonstrate for the first time that VACV was effective in preventing and reducing circulating tumor cells in mice bearing human tumor xenografts. Importantly, a single intra-peritoneal delivery of VACV resulted in a dramatic decline in the number of tumor cells in the ascitic fluid from a patient with gastric cancer. Taken together, these results suggest VACV to be a useful tool for quantitative detection of live tumor cells in liquid biopsies as well as a potentially effective treatment for reducing or eliminating live tumor cells in body fluids of patients with metastatic disease.
Virotherapy using oncolytic vaccinia virus (VACV) strains is one promising new strategy for canine cancer therapy. In this study we describe the establishment of an in vivo model of canine soft tissue sarcoma (CSTS) using the new isolated cell line STSA-1 and the analysis of the virus-mediated oncolytic and immunological effects of two different Lister VACV LIVP1.1.1 and GLV-1h68 strains against CSTS. Cell culture data demonstrated that both tested VACV strains efficiently infected and destroyed cells of the canine soft tissue sarcoma line STSA-1. In addition, in our new canine sarcoma tumor xenograft mouse model, systemic administration of LIVP1.1.1 or GLV-1h68 viruses led to significant inhibition of tumor growth compared to control mice. Furthermore, LIVP1.1.1 mediated therapy resulted in almost complete tumor regression and resulted in long-term survival of sarcoma-bearing mice. The replication of the tested VACV strains in tumor tissues led to strong oncolytic effects accompanied by an intense intratumoral infiltration of host immune cells, mainly neutrophils. These findings suggest that the direct viral oncolysis of tumor cells and the virus-dependent activation of tumor-associated host immune cells could be crucial parts of anti-tumor mechanism in STSA-1 xenografts. In summary, the data showed that both tested vaccinia virus strains and especially LIVP1.1.1 have great potential for effective treatment of CSTS.
Background: Oncolytic viruses, including vaccinia virus (VACV), are a promising alternative to classical mono-cancer treatment methods such as surgery, chemo- or radiotherapy. However, combined therapeutic modalities may be more effective than mono-therapies. In this study, we enhanced the effectiveness of oncolytic virotherapy by matrix metalloproteinase (MMP-9)-mediated degradation of proteins of the tumoral extracellular matrix (ECM), leading to increased viral distribution within the tumors. Methods: For this study, the oncolytic vaccinia virus GLV-1h255, containing the mmp-9 gene, was constructed and used to treat PC-3 tumor-bearing mice, achieving an intra-tumoral over-expression of MMP-9. The intra-tumoral MMP-9 content was quantified by immunohistochemistry in tumor sections. Therapeutic efficacy of GLV-1h255 was evaluated by monitoring tumor growth kinetics and intra-tumoral virus titers. Microenvironmental changes mediated by the intra-tumoral MMP-9 over-expression were investigated by microscopic quantification of the collagen IV content, the blood vessel density (BVD) and the analysis of lymph node metastasis formation. Results: GLV-1h255-treatment of PC-3 tumors led to a significant over-expression of intra-tumoral MMP-9, accompanied by a marked decrease in collagen IV content in infected tumor areas, when compared to GLV-1h68-infected tumor areas. This led to considerably elevated virus titers in GLV-1h255 infected tumors, and to enhanced tumor regression. The analysis of the BVD, as well as the lumbar and renal lymph node volumes, revealed lower BVD and significantly smaller lymph nodes in both GLV-1h68- and GLV-1h255- injected mice compared to those injected with PBS, indicating that MMP-9 over-expression does not alter the metastasis-reducing effect of oncolytic VACV. Conclusions: Taken together, these results indicate that a GLV-1h255-mediated intra-tumoral over-expression of MMP-9 leads to a degradation of collagen IV, facilitating intra-tumoral viral dissemination, and resulting in accelerated tumor regression. We propose that approaches which enhance the oncolytic effect by increasing the intra-tumoral viral load, may be an effective way to improve therapeutic outcome.